4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vistagen Therapeutics, Inc. (VTGN) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 41 employees. Its market capitalization is roughly $10 million. In the fiscal year ended 2026-03-31, VTGN reported $1M in revenue and ($70M) in net income.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
Interactive charts & full statements → Open the VTGN valuation workbench →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $1M | ($0M) | — |
| Operating Income (EBIT) | ($72M) | ($56M) | ($33M) | ($59M) | — |
| Net Income | ($70M) | ($51M) | ($29M) | ($59M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($17M) | ($20M) | ($20M) | ($16M) | ($14M) | — |
| Net Income | ($16M) | ($19M) | ($19M) | ($15M) | ($14M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $49M | $84M | $124M | $21M | — |
| Total Liabilities | $13M | $14M | $9M | $9M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VTGN viewer.
About TickerBase · Data methodology & sources